Your browser doesn't support javascript.
loading
Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial.
Yuan, Xiaoyong; Guo, Xiaohui; Zhang, Junqing; Dong, Xiaolin; Lu, Yibing; Pang, Wuyan; Gu, Shenghong; Niemoeller, Elisabeth; Ping, Lin; Nian, Gaowei; Souhami, Elisabeth.
Affiliation
  • Yuan X; Peking University First Hospital, Beijing, China.
  • Guo X; Peking University First Hospital, Beijing, China.
  • Zhang J; Peking University First Hospital, Beijing, China.
  • Dong X; Jinan Central Hospital, Jinan, China.
  • Lu Y; The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Pang W; Huaihe Hospital of Henan University, Kaifeng, China.
  • Gu S; Sanofi, Shanghai, China.
  • Niemoeller E; Sanofi, Frankfurt, Germany.
  • Ping L; Sanofi, Bridgewater, NJ, USA.
  • Nian G; Sanofi, Beijing, China.
  • Souhami E; Sanofi, Paris, France.
Diabetes Obes Metab ; 24(11): 2182-2191, 2022 11.
Article in En | MEDLINE | ID: mdl-35762489
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Hypoglycemia Type of study: Clinical_trials Limits: Adult / Humans / Middle aged Country/Region as subject: Asia Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2022 Type: Article Affiliation country: China
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Hypoglycemia Type of study: Clinical_trials Limits: Adult / Humans / Middle aged Country/Region as subject: Asia Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2022 Type: Article Affiliation country: China